Theranautilus: The Startup Transforming Dental Care with Nanotechnology In a groundbreaking move, Theranautilus, a deep-tech startup based in Bengaluru, has secured $1.2 million in seed funding to take
In a groundbreaking move, Theranautilus, a deep-tech startup based in Bengaluru, has secured $1.2 million in seed funding to take its innovative nanorobotics technology into the world of dental care. The funding round was led by Pi Ventures, with participation from Golden Sparrow Ventures and prominent angel investors, including Abhishek Goyal, CEO of Tracxn, and Lalit Keshre, CEO of Groww.
Theranautilus aims to become the first global startup to commercialize nanorobotics-based medical devices. Initially, the focus will be on treating dental hypersensitivity, a common yet often painful condition that affects millions worldwide.
Founded in 2020 by Professor Ambarish Ghosh, Dr. Debayan Dasgupta, and Dr. Peddi Shanmukh Srinivas, Theranautilus is set to revolutionize dental care. The startup was incubated at the Indian Institute of Science (IISc) and has developed groundbreaking nanorobotic solutions capable of navigating the delicate tissues inside the mouth to deliver biocompatible materials. These materials are used to repair damaged tissue and offer a long-term solution to dental problems, particularly dental hypersensitivity.
This technology is a significant improvement over traditional treatments, such as specialized toothpaste or mouthwashes, which only offer temporary relief. By using nanorobots, Theranautilus offers a minimally invasive, long-lasting solution. These precision-engineered nanorobots can be activated externally to form bio-mimetic structures, providing relief in just a 10-minute procedure.
The real magic lies in the precision and effectiveness of the nanorobots. These tiny robots are designed to navigate through dental tissues, identifying and repairing damaged areas at the microscopic level. When triggered externally, the robots create structures that mimic natural tissue, delivering lasting relief to patients suffering from dental hypersensitivity.
The beauty of this technology is that it’s non-invasive and can be done in a short amount of time, offering patients a quick solution to a common dental issue. But this is just the beginning. Theranautilus has plans to extend the use of its nanorobotic technology to treat other medical conditions, including cancer therapy.
Theranautilus has big plans for the future, and the recent funding will help the company move closer to its goals. The startup is set to establish an ISO-certified manufacturing facility that will help them scale production of their nanorobots. This facility will be crucial in the lead-up to human trials, which are expected to start in 2025.
Alongside this, Theranautilus plans to file international patents to protect its intellectual property and maintain its edge in the rapidly growing field of nanomedicine.
According to Sohil Bhagat, Principal at Pi Ventures, “Theranautilus’s treatment for dental hypersensitivity could completely change the multi-billion-dollar global dental industry. Their technology holds promise not only for dental care but could also open new doors in various other medical fields.”
Theranautilus is not just another dental care company. By merging cutting-edge nanotechnology with the growing demand for non-invasive treatments, the startup is positioning itself to make a massive impact on the healthcare industry. Their nanorobotic platform offers a versatile solution that could be applied to a wide range of medical challenges, from cancer treatment to wound healing.
For now, the company is focused on dental hypersensitivity, a condition that affects millions globally. This simple yet effective solution could transform how we think about dental care, offering patients long-term relief with minimal effort.
The implications of this technology go beyond just dental health. As the world continues to explore the potential of nanotechnology, Theranautilus is one of the leaders in applying these advances to medicine. The startup’s ability to scale up its operations and enter human trials will be a crucial milestone for the future of nanomedicine.
The path ahead for Theranautilus is exciting, as the company moves closer to clinical trials and further solidifies its position as a leader in nanotechnology-driven healthcare. With their innovative approach to dental hypersensitivity, they are poised to become a significant player in the global healthcare industry.
As they continue to scale production, develop their manufacturing facility, and prepare for human trials, Theranautilus is set to disrupt not just dental care but the larger medical field with its groundbreaking nanorobotics technology.
